Most people diagnosed with mesothelioma live between 12 and 21 months, though survival varies widely depending on where the cancer is located, how early it’s caught, and what treatments are possible. Some patients live five years or longer, and a small number have survived well beyond a decade. The numbers can feel overwhelming, but understanding what drives them helps you make sense of your own situation.
Overall Survival by Stage
The five-year relative survival rate for pleural mesothelioma (the most common form, affecting the lining of the lungs) is about 15% across all stages combined, based on patients diagnosed between 2015 and 2021. Broken down by how far the cancer has spread, the picture shifts considerably. Localized disease, where the cancer remains within the pleura, carries a 23% five-year survival rate. Regional disease, meaning spread to nearby structures or lymph nodes, drops to 15%. Distant disease, where the cancer has reached other parts of the body, still has an 11% five-year survival rate.
For a concrete example of what this looks like in real life: a 40-year-old man diagnosed with localized pleural mesothelioma has a life expectancy of roughly 6 additional years from diagnosis. If that same man is diagnosed with distant disease, his life expectancy is closer to 4 years. Women consistently do better at every stage, with the same localized diagnosis yielding about 9 years of additional life expectancy for a 40-year-old woman.
Peritoneal Mesothelioma Has a Better Outlook
Peritoneal mesothelioma, which develops in the lining of the abdomen, generally allows for longer survival than the pleural form. A 40-year-old man with localized peritoneal mesothelioma has a life expectancy of roughly 11 years from diagnosis, compared to 6 years for pleural. Even with distant peritoneal disease, life expectancy sits around 6 to 8 years depending on sex.
Much of this advantage comes from a treatment called cytoreductive surgery combined with heated chemotherapy delivered directly into the abdomen. This approach has produced median survival times of about 50 months in well-selected patients. A large international registry of 405 patients treated this way found a median survival of 53 months, with 47% of patients alive at five years. Some studies report median survival as high as 92 months for patients who respond well to this treatment.
Cell Type Makes a Major Difference
Mesothelioma tumors are classified into three cell types, and which one you have is one of the strongest predictors of how long you’ll live.
- Epithelioid is the most common type and carries the best prognosis. Patients with pure epithelioid mesothelioma have a median survival of about 20 months.
- Biphasic tumors contain a mix of epithelioid and sarcomatoid cells. They account for 10 to 15% of cases, and prognosis depends heavily on the ratio. Patients with more than 50% epithelioid cells survive a median of about 12 months, while those with less than 50% survive closer to 7 months.
- Sarcomatoid is the most aggressive type. Without treatment, most patients die within 5 to 6 months of diagnosis.
How Treatment Changes the Timeline
For patients whose cancer cannot be surgically removed, systemic therapy is the primary option and typically provides a median survival of about one year. The treatment landscape improved meaningfully when a combination immunotherapy regimen was approved as a first-line option. In a major clinical trial, patients receiving this combination lived a median of 18.1 months, compared to 14.1 months for those on standard chemotherapy. That four-month improvement may sound modest, but it represents a meaningful shift for a cancer that has historically been very difficult to treat.
For patients who are candidates for surgery, the type of operation matters. A less aggressive procedure that removes the diseased lining while preserving the lung has shown better median survival (about 16 months) compared to the more radical approach of removing the entire lung along with the lining (about 12 months), based on a large review of over 600 patients. Preserving lung function appears to give patients a better overall trajectory.
Age and Sex Affect Outcomes
Younger patients consistently live longer after a mesothelioma diagnosis, in part because they tend to tolerate aggressive treatments better and are more likely to be candidates for surgery. Age also reflects the body’s overall resilience and ability to recover.
Women have a statistically significant survival advantage over men, even after accounting for age, cell type, and overall health. A large UK study of over 10,000 patients found that women had a 15% lower risk of death compared to men. This held true even when researchers looked only at patients with the same cell type and similar physical condition. Higher estrogen levels may play a protective role, though the exact mechanism is still being studied. The gender gap is particularly notable because mesothelioma overwhelmingly affects men, who account for roughly 88% of cases due to higher historical rates of asbestos exposure.
Some Patients Live Far Longer Than Expected
While median survival numbers describe the middle of the range, there are patients who far outlive their prognosis. Documented long-term survivors include people living 10, 16, and even 17 years after diagnosis. These cases are not the norm, but they are not isolated miracles either. Long-term survival tends to cluster among patients who are younger at diagnosis, have epithelioid cell type, catch the disease at an earlier stage, and receive multimodal treatment combining surgery with other therapies.
The five-year survival rate of 15% means that roughly 1 in 7 patients diagnosed today will be alive five years later. For peritoneal mesothelioma patients treated with surgery and heated chemotherapy, that number climbs to as high as 1 in 2. These figures have improved over the past two decades as immunotherapy and surgical techniques have advanced, and they represent a meaningful departure from the grim statistics that dominated earlier eras of this disease.